CoQ10 is a key electron carrier in the mitochondrial respiratory chain and an important lipid-soluble antioxidant; depletion reduces cellular energy output and increases susceptibility of membranes and LDL particles to oxidative damage. This medication is commonly used for Diabetes.
Mechanistic and clinical studies link lower CoQ10 status with impaired oxidative phosphorylation and higher markers of oxidative stress, particularly in tissues with high metabolic demand such as myocardium and skeletal muscle.
Littarru GP, Tiano L. Clinical aspects of coenzyme Q10: cardiology and beyond. Antioxid Redox Signal. 2010;12(10):1535-1546.; Mancini A et al. Coenzyme Q10: clinical applications in cardiovascular diseases. Antioxidants (Basel). 2020;9(4):341.
Some side effects may be linked to nutrient depletion caused by this medication.
Long term treatment with Biguanides, such as Metformin or Metformin combinations with other drugs, are found in research to reduce vitamin B12 absorption due to it hindering the activity of a calcium-dependent mechanism. Insufficient levels of vitamin B12 can lead to higher circulating homocysteine levels and the elevated risk of neurological problems and cardiovascular diseases.
Biguanide (anti-diabetic) drugs have been found in scientific evidence to decrease serum levels of coenzyme Q10. Type 2 diabetes can increase oxidative stress in the body, weakening its defenses and potentially harming cells. CoQ10, a powerful antioxidant, plays a crucial role in protecting cells from this damage. CoQ10 supplementation may help restore these levels, potentially improving mitochondrial function and protecting the kidneys from damage.
Research has shown that anti-diabetic Biguanide drugs may reduce folic acid absorption. Folic acid is a powerful antioxidant and low levels make the body more susceptible to oxidative stress, which can damage enzymes involved in homocysteine metabolism, and subsequently increase its accumulation. Elevated levels of homocysteine (hyperhomocysteinemia) are a risk factor for various health problems including cardiovascular diseases, neurological problems, osteoporosis, and vision problems.
Biguanides, such as Metformin or Metformin combinations with other drugs, may contribute to reduced levels of thiamine (vitamin B1) in end-stage renal failure patients. Research has found metformin encephalopathy present in patients on hemodialysis for end-stage diabetic renal failure (ESRD). Patients with ESRD should consider having thiamine (vitamin B1) status monitored and supplementing with thiamine when levels are insufficient or deficient.